

LITERATURA

1. Majewska A, Mlynarczyk-Bonikowska B. 40 years after the registration of acyclovir: Do we need new anti-herpetic drugs? *Int J Mol Sci.* 2022;23(7):3431.
2. Nishii R, Mizuno T, Rehling D, et al. NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. *Nat Commun.* 2021;12(1):4181.
3. Brandariz-Núñez D, Correas-Sanahuja M, Maya-Gallego S, et al. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. *J Clin Pharm Ther.* 2021;46(4):918-926.
4. Abuhelwa Z, Beran A, Venkataramany BS, et al. <https://pubmed.ncbi.nlm.nih.gov/35509998/> – affiliation-1 Concurrent nephrotoxicity and neurotoxicity induced by oral valacyclovir in a patient with previously normal kidney function. *Cureus.* 2022;14(3):e23693.
5. Kaciřova I, Urinovska R, Sagan J. Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice. *Biomed Pharmacother.* 2022;156:113852.
6. Årlemalm A, Helldén A, Karlsson L, et al. Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC-MS/MS. *Biomed Chromatogr.* 2022;36(4):e5315.
7. Sadjadi SA, Regmi S, Chau T. Acyclovir neurotoxicity in a peritoneal dialysis patient: Report of a case and review of the pharmacokinetics of acyclovir. *Am J Case Rep.* 2018;19:1459-1462.
8. Maximova N, Nisticò D, Luci G, et al. Population pharmacokinetics of intravenous acyclovir in oncologic pediatric patients. *Front Pharmacol.* 2022;13:865871.
9. Gunness P, Aleksa K, Bend J, et al. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. *Transl Res.* 2011;158(5):290-301.
10. Al-Alawi AM, Al-Maqbali JS, Al-Adawi M, et al. Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity. *Saudi Pharm J.* 2022;30(6):874-877.
11. Helldén A, Odar-Cederlöf I, Larsson K, et al. Death delusion. *BMJ.* 2007;335(7633):1305.
12. Helldén A, Odar-Cederlöf I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. *Nephrol Dial Transplant.* 2003;18:1135-1141.
13. Helldén A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. *J Antimicrob Chemother.* 2006;57(5):945-949.
14. Cotard J. Du délire des négations. *Arch Neurol.* 1882;4:152-170, 282-296.
15. Robertson KM, Harvey CL, Cunningham JM. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. *J Med Case Rep.* 2020;14(1):156.
16. Abdalla S, Briand C, Oualha M, et al. Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens. *Antimicrob Agents Chemother.* 2020;64(12):e01426-20.
17. Abdul-Aziz MH, Alffenaar JWC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. *Intensive Care Med.* 2020;46(6):1127-1153.
18. Cies JJ, Moore WS, Miller K, et al. Therapeutic drug monitoring of continuous-infusion acyclovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. *Pharmacotherapy.* 2015;35(2):229-233.
19. Euler M, Axelsson G, Helldén A. Differential diagnosis of central nervous system involvement in a patient treated with acyclovir. *Ther Drug Monit.* 2013;35(4):417-419.
20. Lycke J, Andersen O, Svennerholm B, et al. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. *J Antimicrob Chemother.* 1989;24(6):947-954.
21. Yang HH, Hsiao YP, Shih HC, et al. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. *Int J Dermatol.* 2007;46(8):883-884.
22. Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. *Crit Care.* 2020;24(1):195.
23. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. *J Infect Dis.* 1988;157(2):385-388.
24. Urinovska R, Kaciřova I, Sagan J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in human serum by ultra-high-performance liquid chromatography-tandem mass spectrometry. *J Sep Sci.* 2021;44(16):3080-3088.